Disease | arteriosclerosis |
Symptom | C0018801|heart failure |
Sentences | 9 |
PubMedID- 25609972 | There were six deaths reported after week 54, five of them in patients who received golimumab: biventricular heart failure in a patient with marked atherosclerosis, myocardial infarction in a patient with a history of myocardial infarction, metastatic gallbladder adenocarcinoma, sepsis, and accidental nitrous oxide overdose. |
PubMedID- 24716810 | Redistribution of heart failure as the cause of death: the atherosclerosis risk in communities study. |
PubMedID- 25983559 | Thus, mcs are key immune cells capable of promoting multiple stages of the pathogenesis of atherosclerosis that lead to mi and heart failure. |
PubMedID- 24612513 | Atenolol-induced decreases in heart rate and cardiac output and transitory peaks of variation of arterial pressure due to poorer pressure regulation in very old animals, which have a myocardium heavily degenerated by aging-related damage and the main systemic arteries stiffened by atherosclerosis, can lead to heart failure and be fatal. |
PubMedID- 25961230 | In addition, the administration of mineralocorticoid receptor antagonists ameliorates endothelium-dependent relaxation in models of both hypertension and atherosclerosis, and in patients with heart failure. |
PubMedID- 19500820 | Narrowing of the arteries due to atherosclerosis may lead to congestive heart failure (chf). |
PubMedID- 21349192 | The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new subclinical atherosclerosis and sudden death. |
PubMedID- 20716703 | The potentially modifiable burden of incident heart failure due to obesity: the atherosclerosis risk in communities study. |
PubMedID- 21375762 | The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. |
Page: 1